Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | 23,418 | 14,074 | 37,466 | 23,195 |
| General and administrative | 8,099 | 5,242 | 14,953 | 10,789 |
| Total operating expenses | 31,517 | 19,316 | 52,419 | 33,984 |
| Loss from operations | (31,517) | (19,316) | (52,419) | (33,984) |
| Other (expense) income: | ||||
| Change in fair value of derivative liability | (1,010) | (2,530) | (530) | (2,150) |
| Change in fair value of contingent consideration | (6,574) | — | (6,574) | — |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's G&A?
- Avalo Therapeutics (AVTX) reported G&A of $8.1M in Q2 2026.
- How has Avalo Therapeutics's G&A changed year-over-year?
- Avalo Therapeutics's G&A increased by 54.5% year-over-year, from $5.24M to $8.1M.
- What is the long-term trend for Avalo Therapeutics's G&A?
- Over 3 years (2021 to 2025), Avalo Therapeutics's G&A has grown at a -2.4% compound annual growth rate (CAGR), from $24.66M to $22.9M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Avalo Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude